Targeting CCL2–CCR2 axis has shown a good outcome in mouse models (Li et al., 2017; Xu et al., 2021b), but anti-CCL2 mAbs or CCR2 antagonists are mainly used to treat immune diseases in the clinical trials. This evidence concerns the gene CCR2 and immune system disorder.